You're making a lot of assumptions that are faulty....
1. You're assuming that NVS/Sandoz has influence and/or control over the timing and the approval of M-copax. The ANDA has already been filed w/ the FDA, and now FDA has sole discretion if and when to approve. If NVS/Sandoz wanted to delay the approval of M-copax, they wouldn't have filed the ANDA to begin with (or at least would have delayed it when they could exert influence).
2. From a MNTA buyout perspective, it could be possible that NVS/Sandoz may want to delay M-copax approval. But from a cash flow perspective, they'll want M-copax approval AS SOON AS POSSIBLE.
3. If billions are at stake, MNTA would receive a takeover offer TODAY. MNTA is trading at less than $400M ex cash, which is nothing compared to the revenues and mkt cap of the large biotech & pharmas. Are u saying that potential suitors are waiting until MNTA's mkt cap falls closer to its cash value? I highly doubt that.